New Directions
in New Therapies

About Wedge

What do you do when you're a serial entrepreneur and you have friends and family members being afflicted with Alzheimer's disease? You research the disease traits, develop a novel technology and build a company to attack it head on.

That foundation is what fuels Wedge Therapeutics everyday. As a privately -held medical device development company formed in Minnesota in 2013, a hotbed for medical device advances over the last 30 years - we believe that we are on track to be the next one.

Leveraging our intellectual property, Wedge is positioned to be the leader in a $20 billion market because its' device strategy holds the ability to make a huge impact for people afflicted with Alzheimer's disease (AD) and other neurodegenerative diseases (i.e., Parkinson's disease, Depression, Epilepsy, etc.).

In relation, our device therapy leverages the same application premise as other successful applications of modern electrophysiology like Deep Brain Stimulation (DBS), and other neurostimulation techniques that target peripheral nerves. But the big difference is that the SONS System is minimally-invasive and will provide a reliable, inexpensive and widely available therapy that can be performed quickly and accurately by a general practitioner in any out-patient setting, to enable swift intervention and to bring about a path to a more functional life.

 *SONS is currently designated as an investigational device and limited by U.S. Federal law to investigational use